Lexeo Therapeutics Reports Interim Data from P-I/II Study of LX2006 to Treat Friedreich Ataxia Cardiomyopathy
Shots:
- The 52wk. P-I/II (SUNRISE-FA) study assesses LX2006 in FA cardiomyopathy patients across 3 dose-ascending cohorts. Trial will proceed to cohort 3 (1.2x10^12 vg/kg); 1 subject has been dosed & at least 3 are expected
- Study (n=8 & ≥6mos. follow-up) showed >10% LVMI reduction in 50% of overall patients & 75% of those with elevated LVMI at 12mos.; mean LVMI reduction: 11.4% (12mos.) & 18.3% (18mos.) in elevated LVMI group; reduction in LV wall thickness: 13.6% at 12mos.
- High-sensitivity troponin I reduced by 53.3% avg. in all patients at 12mos.; frataxin protein expression increased in 3/3 (assessed by LCMS) & 2/2 evaluable patients (assessed by IHC). Further details incl. another cardiac biopsy from cohort 2 is anticipated in Sep 2024
Ref: LEXEO Therapeutics | Image: LEXEO Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
